Our comprehensive portfolio provides multi-dimensional solutions tailored to diverse research objectives, covering major solid tumors including Lung Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Breast Cancer, Thyroid Cancer, Melanoma, and Glioma. We offer dedicated panels specifically designed for Lung Cancer, Colorectal/Gastric Cancer (CRC/GC), and Glioma. Our assays detect a wide range of genomic alterations—SNVs, Indels, CNVs, Fusions, MSI, and TMB—and are compatible with diverse sample types such as FFPE tissue and blood-derived ctDNA.
Solid Tumor NGS Panel Product Categories
1. Pan Cancer
| Product | Variant Type | Gene Count | Enrichment Method |
|---|---|---|---|
| CDCap™ Comprehensive Cancer Panel Kit | SNV, Indel, CNV, Fusion, MSI, TMB | 641 | Hybridization Probe Capture |
| CDCap™ Solid Tumor Mid Panel Kit | SNV, Indel, Fusion, CNV, MSI | 122 | Hybridization Probe Capture |
| CDCap™ Solid Tumor HotSpot Panel Kit | SNV, Fusion, CNV | 49 | Hybridization Probe Capture |
| CDCap™ Solid Tumor Fusion RNA Panel Kit | SNV, Fusion, Gene Expression | 105 | Hybridization Probe Capture |
2. Lung cancer only
| Product | Variant Type | Gene Count | Enrichment Method |
|---|---|---|---|
| CDCap™ Lung Cancer Panel Kit | SNV, Indel, Fusion, CNV | 23 | Hybridization Probe Capture |
3. Colorectal/Gastric cancer only
| Product | Variant Type | Gene Count | Enrichment Method |
|---|---|---|---|
| CDAmp™ Colorectal/Gastric Cancer Panel Kit | SNV, Indel, Fusion, CNV | 36 | Multiplex PCR Amplification |
4. Glioma only
| Product | Variant Type | Gene Count | Enrichment Method |
|---|---|---|---|
| CDAmp™ Glioma Panel Kit | SNV, Indel, CNV | 13(+1p19q10q) | Multiplex PCR Amplification |
Solid Tumor Sequencing Service
- Rigorous choice of sequencing strategies, including whole genome, whole exome, and gene panels
- Stringent quality control throughout the pipeline workflow to ensure sequencing accuracy and reproducibility
- Disease databases and data analysis customized to your needs
- Application for Cancer-related mechanism research、Biomarker discovery、Therapeutic target discovery and Drug target discovery
Advantages of NGS in Solid Tumor Research
Overcomes Traditional Limitations & Sets New Standards
NGS transcends conventional tumor classification by establishing comprehensive molecular profiling as the current standard (per CAP/ESMO guidelines). It enables highly sensitive analysis of key genes across major solid tumors (e.g., lung, colon, breast), detecting rare somatic mutations, low-frequency variants, and tumor heterogeneity undetectable by traditional methods.
Enables Comprehensive Genomic Profiling (CGP)
Through targeted panels, NGS efficiently identifies complex alterations—including structural variants, MSI, TMB, and HRD (see CDCap™ HRR+HRD Panel Kit)—in a high-throughput, cost-effective manner. Its exceptional sensitivity for challenging samples (e.g., low-DNA/tumor content) reveals critical biomarkers and subclones, advancing cancer research.
Why chose CD Genomics
Comprehensive Coverage
We deliver complete solid tumor detection and comprehensive variant analysis.
Optimized Cost-Efficiency
Our Advanced Biosynthesis Technologies reduce costs while maximizing efficiency.
Scalable & Customizable Solutions
Build upon our proven, ready-to-use panels to seamlessly add targeted genes/regions, or design entirely new panels focused on your specific targets of interest.
